Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/2/2025

Management of Barrett's Esophagus

Initial Assessment and Symptom Control

  • The management of Barrett's esophagus requires a structured approach including symptom control, endoscopic surveillance, and treatment of dysplasia or early cancer, with treatment decisions based on the degree of dysplasia and presence of visible lesions 1
  • Offer a clinical consultation to newly diagnosed patients to discuss cancer risk, surveillance plans, and symptom control 1, 2
  • Provide verbal and written information about the diagnosis, treatment options, and patient support groups 2
  • Follow NICE guidelines on interventions for gastroesophageal reflux disease (GORD) for symptom management 1
  • Do not offer anti-reflux surgery specifically to prevent progression to dysplasia or cancer 3

Surveillance and Diagnosis

  • Use high-resolution white light endoscopy with Seattle biopsy protocol for surveillance 1, 4
  • Ensure diagnosis of dysplasia is confirmed by at least two expert gastrointestinal pathologists to avoid unnecessary interventions 1, 2

Management of Dysplasia and Early Cancer

  • Offer radiofrequency ablation to patients with low-grade dysplasia diagnosed from biopsy samples taken at two separate endoscopies and confirmed by two gastrointestinal pathologists 1, 2
  • Consider endoscopic surveillance at 6-monthly intervals with dose optimization of acid-suppressant medication for indefinite dysplasia 1, 5
  • Offer endoscopic resection of visible oesophageal lesions as first-line treatment for high-grade dysplasia 1, 2
  • Offer endoscopic ablation of any residual Barrett's esophagus after treatment with endoscopic resection for high-grade dysplasia 1, 2

Management of Stage 1 Oesophageal Adenocarcinoma

  • Offer endoscopic resection as first-line treatment for T1a oesophageal adenocarcinoma 1, 6
  • Offer endoscopic ablation of any residual Barrett's esophagus after treatment for T1a oesophageal adenocarcinoma 1, 6
  • For patients fit for surgery and at high risk of cancer progression (e.g., incomplete endoscopic resection, lymphovascular invasion): offer oesophagectomy for T1b oesophageal adenocarcinoma 1, 6
  • For patients unfit for oesophagectomy but at high risk of cancer progression: consider radiotherapy (alone or with chemotherapy) for T1b oesophageal adenocarcinoma 7, 8

Prevention and Risk Reduction

  • Do not offer aspirin to prevent progression to oesophageal dysplasia and cancer 1, 4
  • For staging suspected T1b oesophageal adenocarcinoma, consider EUS for nodal staging 1, 5
  • Do not use CT before endoscopic resection for staging suspected T1 oesophageal adenocarcinoma 1, 5